- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01584908
Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients
December 31, 2014 updated by: University of Alberta
Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients(AdVEnTR)
Influenza is an important public health problem.
Organ transplant patients are particularly susceptible to severe disease.
Also, they shed higher quantities of virus for longer durations, leading to greater contagious potential, thereby potentially serving as nodes of spread in the community.
Therefore, improved strategies to prevent influenza in this population is an important public health concern.
Standard vaccination is poorly immunogenic post-transplant and new vaccine strategies are needed.
Adjuvanted vaccines contain molecules that create a strong local inflammatory response and they attract immune cells to the site of injection, increasing the immunogenicity of the vaccine antigen.
Recently seasonal influenza vaccines containing adjuvants have become available in Canada but have only limited information in transplant patients.
This randomized trial is designed to assess the immunogenicity of an adjuvanted vaccination strategy compared to a standard vaccine for seasonal influenza in a cohort of adult organ transplant recipients.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
68
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada
- University of Alberta Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
adult kidney tranplant recipients
Description
Inclusion Criteria:
Adult kidney transplant recipients Greater than 3 months post-transplant
Exclusion Criteria:
Has already received influenza vaccination for 2012-2013 season Egg allergy Previous life-threatening reaction to influenza vaccine (i.e. Guillain Barre Syndrome) Ongoing therapy for rejection Febrile illness in the past two weeks Unable to provide informed consent Unable to comply with study protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (Actual)
April 1, 2014
Study Completion (Actual)
November 1, 2014
Study Registration Dates
First Submitted
April 23, 2012
First Submitted That Met QC Criteria
April 24, 2012
First Posted (Estimate)
April 25, 2012
Study Record Updates
Last Update Posted (Estimate)
January 1, 2015
Last Update Submitted That Met QC Criteria
December 31, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UofA - AdVEnTR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Canadian Immunization Research NetworkCHU de Quebec-Universite Laval; McGill University Health Centre/Research Institute... and other collaboratorsActive, not recruitingAvian Influenza | H5N1 Virus | H5N1 Influenza | Avian Influenza A VirusCanada
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Avian Influenza | H1N1 InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...University of Oxford; Wellcome Trust; World Health OrganizationCompletedInfluenza | Avian Influenza | Severe InfluenzaSingapore, Thailand, Vietnam
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
Ab&B Bio-tech Co., Ltd.JSYither Biotech Co., LtdActive, not recruitingInfluenza | Influenza VaccineChina
-
Novartis VaccinesCompletedProphylaxis of Avian InfluenzaFinland
-
Ab&B Bio-tech Co., Ltd.JSYither Biotech Co., LtdActive, not recruitingClinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderInfluenza | Influenza VaccineChina